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Background: Conventional categorical criteria have limitations in assessing the prevalence
and severity of depressive mixed state (DMX). Thus, we have developed a new scale for
screening and quantiﬁcation of DMX and examined the symptomatological structure and
severity of DMX in individuals with major depressive episode (MDE).
Methods: Subjects were 154 patients with MDE (57 males and 97 females; age 13–83
years). Our original Japanese version of the self-administered 12-item questionnaire to assess
DMX (DMX-12), together with the Quick Inventory of Depressive Symptomatology Self-
Report Japanese version (QIDS-SR-J) and global assessment of functioning, were adminis-
tered to each participant. The symptomatological structure of the DMX-12 was examined by
exploratory factor analysis. Multiple regression analyses were used to analyze factors con-
tributing to the DMX-12 scale. The relationships of this scale with categorical diagnoses
(mixed depression by Benazzi and mixed features by DSM-5) were also investigated.
Results: A three-factor model of the DMX-12 was extracted from exploratory factor
analysis, namely, “spontaneous instability”, “vulnerable responsiveness”, and “disruptive
emotion/behavior”. Multiple regression analyses revealed that age was negatively correlated
with total DMX-12 score, while bipolarity and the QIDS-SR-J score were positively corre-
lated. A higher score on the disruptive emotion/behavior subscale was observed in patients
with mixed depression and mixed features.
Conclusion: The DMX-12 seems to be useful for screening DMX in conjunction with
conventional categorical diagnoses. Severely depressed younger subjects with potential
bipolarity are more likely to develop DMX. The disruptive emotion/behavior subscale of
the DMX-12 may be the most helpful in distinguishing patients with DMX from non-mixed
patients.
Keywords: major depressive episode, depressive mixed state, spontaneous instability,
vulnerable responsiveness, disruptive emotion/behavior
Introduction
Depressive mixed state (DMX) has been regarded as a temporary mixture of bipolar
components with depressive psychopathology.1 Spontaneous verbalization of DMX
symptoms is usually difﬁcult for patients, especially when clinicians interview them
mainly focusing on typical depressive symptoms, which may easily lead to the
underdiagnosis of DMX. However, pharmacological treatments, mainly with anti-
depressants, may provoke impulsive and risky behavior, including self-harm and
suicide attempts, in patients with DMX.2,3 Therefore, it is highly recommended for
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clinicians to quickly diagnose such mixed psychopathol-
ogy and respond appropriately to it as soon as possible for
necessary risk management.
Kraepelin described that the mixed state is not a rare
phenomenon and could be observed as various combina-
tions of asynchronous cycles of mood, will, and thought
during the course of mood disorders.4 However, the opera-
tional criteria used by the Diagnostic and Statistical
Manual of Mental Disorders, 4th Edition, Text Revision
(DSM-IV-TR)5 narrowly deﬁned a “mixed episode” as a
combination of full manic and major depressive manifes-
tations only for bipolar I disorder, which resulted in
strictly limited diagnosis for mixed psychopathology dur-
ing major depressive episodes (MDEs).
It was expected that the newer deﬁnition of the mixed
features speciﬁer in the Fifth Edition of DSM (DSM-5)6
would provide some beneﬁcial effects for more sensitive
and extended diagnosis of DMX. However, the prevalence
of DMX still remained unexpectedly low (3.2–7.5%) during
MDEs even after the DSM-5 criteria were applied to mixed
psychopathology.7,8 Several reports7,9–11 have also criticized
the underdiagnosis of DMX even after using the DSM-5
criteria owing to exclusion of overlapping symptoms for
both manic and depressive symptoms, such as distractibility,
irritability, and psychomotor agitation during an MDE,
termed a “dip” into depression by Malhi et al.9 The same
authors9 have also suggested that these non-speciﬁc symp-
toms are rather fundamental to deﬁning DMX. In contrast,
typical hypomanic symptoms as deﬁned for DSM-5 mixed
features (ie, elevated mood, inﬂated self-esteem, decreased
need for sleep, and increased goal-oriented activity) have
been reported to be very infrequently observed during
MDEs,8,12 and thus seem to be too insensitive to assess
psychopathology and its severity in DMX.
Another study has also reported that aggression in
MDEs is most associated with DMX.13 The deﬁnition of
“mixed depression” by Benazzi,12,14,15 including these
non-speciﬁc symptoms, widened the range of diagnosis
for clinically relevant DMX (12.8−32.3% even in major
depressive disorder).8,16 Thus, the prevalence of DMX has
varied widely depending on its deﬁnition by various cri-
teria. As another problem, these criteria are unlikely to be
suitable for correct assessment of the severity of DMX.
Consequently, these ﬁndings suggest limitations to the
categorical diagnosis of DMX.
In a 2016 study, we proposed a postulated model for
depressive psychopathology structured by static/dynamic
and internalized/externalized dimensions, together with its
plausible treatment options, and suggested the necessity of
dimensional approaches to assess various types of depres-
sive symptomatology, such as melancholic depression,
psychotic depression, and mixed depression.17 It is appar-
ent that DSM-56 covers only a part of DMX with com-
bined features of MDEs and typical manic/hypomanic
symptoms. By reviewing previous literature,7,12,18,19 we
have concluded that the inclusion of less speciﬁc but
more frequent mixed symptoms in the criteria of DMX is
essential to increase the sensitivity of screening for DMX
and to assess its severity. For this purpose, it seems neces-
sary to capture the full picture of DMX on the basis of the
broader deﬁnition of mixed depression by Benazzi.12,14,15
Therefore, in the present study, we developed a new scale
for the screening and quantitative determination of DMX,
covering non-speciﬁc but frequent mixed symptoms, and
examined the symptomatological structure and severity of
DMX using this scale in individuals with MDEs.
Patients and methods
Subjects
Subjects were 154 consecutively recruited patients with
MDE (57 males and 97 females), who visited our clinic
from June 2014 to June 2018. The mean±SD age was 42.6
±17.4 years and the age range was from 13 to 83 years
(age 13–19: n=14; 20–29: n=24; 30–39: n=31; 40–49:
n=33; 50–59: n=22; 60–69: n=20; ≥70: n=10). They
were currently diagnosed as having single or recurrent
MDE(s) according to DSM-5 criteria by two experienced
psychiatrists, and were further classiﬁed into depressive
disorders (n=111) and bipolar and related disorders (n=43).
Patients with substance-related/addictive disorders or neu-
rocognitive disorders were excluded from analyses.
Prescribed drugs were the following: antidepressants
(amitriptyline: 1; imipramine: 2; clomipramine: 1; amoxa-
pine: 1; setiptiline: 1; trazodone: 5; ﬂuvoxamine: 3; parox-
etine: 16; sertraline: 11; escitalopram: 9; milnacipran: 3;
duloxetine: 10; venlafaxine: 2; mirtazapine: 12), antipsy-
chotic drugs (risperidone: 2; paliperidone: 1; quetiapine: 13;
olanzapine: 5; aripiprazole: 19; sulpiride: 13; levomepro-
mazine: 5; chlorpromazine: 1; haloperidol: 1), mood-stabi-
lizing drugs (lithium carbonate: 10; sodium valproate: 16;
lamotrigine: 10; carbamazepine: 1), benzodiazepine anxio-
lytics (alprazolam: 14; ethyl loﬂazepate: 10; lorazepam: 12;
bromazepam: 7; diazepam: 3; etizolam: 26; clonazepam: 9;
and clotiazepam: 3), benzodiazepine hypnotics (brotizolam:
21; ﬂunitrazepam: 17; triazolam: 10; rilmazafone: 3;
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quazepam: 2; nitrazepam: 2; lormetazepam: 1; estazolam:
1), non-benzodiazepine hypnotics (zolpidem: 14; zopi-
clone: 9; eszopiclone: 9), others (methylphenidate: 1; pre-
dnisolone: 1), and no psychoactive drug: 38.
All subjects gave written informed consent to voluntarily
participate in our research. For patients under the age of 18, we
obtained written informed consent not only from the patients
but also from their parents. The data were anonymously trea-
ted during the study. Only coded and grouped data were used
for analyses. An explanation of the purpose of the study,
measures for protection of personal information, and the
right to withdraw from the study were provided to each
participant. This study was conducted in accordance with the
Declaration of Helsinki. The study protocol was approved by
the Ethics Committee of University of the Ryukyus.
Assessment
The self-administered 12-item questionnaire for assessment of
depressive mixed state (DMX-12) in Japanese (Appendix 1)
was developed by us (Table 1), according to previously
reported core features for DMX such as distractibility, irrit-
ability, and psychomotor agitation (inner tension and restless-
ness) and racing/crowded thought,12,18 as well as other
prevalent mixed symptoms, eg, mood lability, overreactivity,
impulsivity, aggression, and risk-taking behavior, pointed out
from previous research.7,19 This scale was translated into
English (Appendix 2) and back-translated into Japanese by
two native speakers of both English and Japanese, followed by
conﬁrmation from all the authors.We used the original version
(in the Japanese language) in the present study. The 12 items
were: hypersensitivity, overreactivity, distractibility, mood
lability, inner tension, dysphoria, racing/crowded thought, rest-
lessness, impulsivity, irritability, aggression, and risk-taking
behavior (Table 1). Each item on the DMX-12 was scored
using four-scale steps according to the frequency of each
symptom (0: never; 1: only occasionally; 2: often; 3: almost
always) during the latest 1-week period of an MDE.
The DMX-12, together with the Quick Inventory of
Depressive Symptomatology Self-Report20 Japanese ver-
sion (QIDS-SR-J) and Global Assessment of Functioning
(GAF),21 were administered to each participant.
Statistical analyses
The symptomatological structure of the DMX-12 was
examined in the overall patients using exploratory factor
analysis after Varimax rotation. The patterns of distribu-
tions in total and subscale scores on the DMX-12 were
analyzed by the Kolmogorov–Smirnov test. Effects of
various factors, including age, gender, number of mood
episodes, duration of illness, education level, bipolarity,
severity of depression, and GAF, on total/subscale scores
on the DMX-12 were examined by multiple regression
analysis. Total and subscale scores on the DMX-12 were
compared between patients with and without an estab-
lished categorical diagnosis of DMX, deﬁned as mixed
depression12,14,15 or mixed features speciﬁer in DSM-5,6
by the Mann–Whitney U-test.
A two-tailed P-value less than 0.05 was regarded as
statistically signiﬁcant. SPSS 16.0 J for Windows (SPSS
Japan, Tokyo, Japan) was used for these statistical
analyses.
Results
Exploratory factor analysis of the DMX-12
Three distinctive components of the DMX-12 were
extracted from exploratory factor analysis (Table 2),
namely, “spontaneous instability” (restlessness, distract-
ibility, racing/crowded thought, mood lability, inner ten-
sion, and impulsivity: Cronbach’s α=0.868), “vulnerable
responsiveness” (hypersensitivity and overreactivity:
Cronbach’s α=0.826), and “disruptive emotion/behavior”
(aggression, irritability, dysphoria, and risk-taking beha-
vior: Cronbach’s α=0.769).
Table 1 The 12-item questionnaire for assessment of depressive
mixed state (DMX-12)
Evaluation item Actual content of the questionnaire
1. Hypersensitivity I am more sensitive and vulnerable than usual to
others' comments and attitudes
2. Overreactivity I tend to overreact to trivial things more than
usual
3. Distractibility I am easily distracted and unable to focus com-
pletely on a task
4. Mood lability My mood changes rapidly in a short time
5. Inner tension I feel so tense that I am unable to relax
6. Dysphoria I get overwhelmed by unpleasant and displeas-
ing feelings
7. Racing/crowded
thought
Many different thoughts run through my head
rapidly and fruitlessly
8. Restlessness I feel restless and unable to stay still
9. Impulsivity I feel like acting impulsively with no regard for
consequences
10. Irritability I get easily irritated for no reason
11. Aggression When someone disagrees with me, I feel like
quarreling with or hitting that person
12. Risk-taking
behavior
I tend to deliberately take risks
Dovepress Shinzato et al
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Prevalence of DMX-12 symptoms
The most frequently observed persistent symptoms of the
DMX-12 (>30%) were hypersensitivity (38.3%), racing/
crowded thought (36.4%), distractibility (34.4%),
overreactivity (33.8%), and inner tension (32.5%), as
shown in Figure 1. Symptoms of vulnerable responsive-
ness and spontaneous instability were more commonly
observed than those of disruptive emotion/behavior during
an MDE (Figure 1).
Distribution of total and subscale scores
on the DMX-12
The distribution of total and the spontaneous instability
subscale scores closely ﬁtted the normal distribution
model by the Kolmogorov–Smirnov test (P>0.05),
whereas a negatively skewed distribution for the vulner-
able responsiveness subscale and a positively skewed dis-
tribution for the disruptive emotion/behavior subscale
were found, as shown in Figure 2. The median (range)
and mean±SD for total scores on the DMX-12 were 18 (0–
33) and 18.0±6.6, respectively. The median subscale
scores (range) for spontaneous instability, vulnerable
responsiveness, and disruptive emotion/behavior were 10
(0–18), 4 (0–6), and 3 (0–11), respectively.
Multiple regression analyses of various
factors affecting the DMX-12
Multiple regression analyses (Table 3) revealed that age
was negatively associated with total DMX-12 (β=−0.300,
P=0.001) and subscale scores for spontaneous instability
Table 2 Exploratory factor analysis of the 12-item questionnaire
for assessment of depressive mixed state (DMX-12) in 154
patients with major depressive episode
Factor loadings
1 2 3
1. Spontaneous instability
(Cronbach’s α=0.868)
Restlessness 0.787 0.260 0.096
Racing/crowded thought 0.709 0.263 0.157
Mood lability 0.682 0.187 0.173
Inner tension 0.675 0.331 0.143
Distractibility 0.623 0.121 0.176
Impulsivity 0.547 0.163 0.293
2. Vulnerable responsiveness
(Cronbach’s α=0.826)
Hypersensitivity 0.245 0.805 0.129
Overreactivity 0.368 0.713 0.279
3. Disruptive emotion/beha-
vior (Cronbach’s α=0.769)
Aggression 0.050 0.119 0.873
Irritability 0.261 0.168 0.717
Dysphoria 0.380 0.383 0.449
Risk-taking behavior 0.376 0.117 0.382
0 10 20 30 40 50
Risk-taking behavior
Aggression
Impulsivity
Irritability
Dysphoria
Mood lability
Restlessness
Inner tension
Overreactivity
Distractibility
Racing/crowded thought
Hypersensitivity
Spontaneous instability Vulnerable responsiveness Disruptive emotion/behavior
(%)
Figure 1 Prevalence of persistent symptoms of the 12-itemquestionnaire for assessment of depressive mixed state (DMX-12) during a major depressive episode.
Shinzato et al Dovepress
submit your manuscript | www.dovepress.com
DovePress
Neuropsychiatric Disease and Treatment 2019:151986
 
N
eu
ro
ps
yc
hi
at
ric
 D
ise
as
e 
an
d 
Tr
ea
tm
en
t d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
15
0.
59
.2
2.
16
9 
on
 0
1-
No
v-
20
19
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
(β=−0.192, P=0.015) vulnerable responsiveness (β=
−0.261, P=0.001), and disruptive emotion/behavior (β=
−0.361, P=0.001). Meanwhile, the scores on the QIDS-
SR-J showed positive correlations with total scores on the
DMX-12 (β=0.465, P=0.001) and any of its subscale
scores for spontaneous instability (β=0.454, P=0.001),
vulnerable responsiveness (β=0.331, P=0.001), and disrup-
tive emotion/behavior (β=0.346, P=0.001). Bipolarity was
positively correlated with the total DMX-12 score
(β=0.174, P=0.031) and disruptive emotion/behavior sub-
scale score (β=0.193, P=0.021).
Categorically diagnosed DMX and the
DMX-12
In the present study, 28 cases (18.2%) showed mixed
depression by Benazzi’s criteria,12,14,15 while seven cases
(4.5%) showed a mixed features speciﬁer during an MDE
according to DSM-56 among the overall 154 patients with
current MDEs. Comparisons of total and subscale scores
on the DMX-12 were made between patients with and
without categorically diagnosed DMX (Table 4). Patients
with mixed depression showed higher scores than those
without mixed depression on total DMX-12 (21.8±6.0 vs
17.2±8.2; P=0.005) and subscale scores of spontaneous
instability (11.7±3.9 vs 9.7±4.9; P=0.042), vulnerable
responsiveness (4.6±1.3 vs 3.7±1.9; P=0.027), and
disruptive emotion/behavior (5.5±2.6 vs 3.8±2.9;
P=0.002). Meanwhile, patients with mixed features
showed higher scores than those without mixed features
only on the disruptive emotion/behavior subscale (6.9±2.7
vs 3.9±2.9; P=0.013).
Discussion
Swann10 has implied that mixed states may be a dimen-
sional property of mood episodes.
Challenging trials for dimensional scales have been con-
ducted to measure mixed states, eg, the General Inventory of
Mixed Affective Symptoms,22 Multidimensional Assessment
of Thymic States,23 and Multiple Visual Analogue Scale of
Bipolarity.24 However, these scales also include many typical
symptoms with hypomania/mania and consist of 20 or more
items, which may not be suitable for a compact assessment to
determine the severity of DMX. The newer Koukopoulos
Mixed Depression Rating Scale, proposed by Sani et al,25
should be noted as a diagnostic tool for objective and sub-
jective assessment. However, in a busy consulting room, it
may be rather time-consuming for clinicians to estimate series
of depressed cases using this scale. These situations prompted
us to develop the DMX-12 as a new and compact quantitative
scale solely for DMX, mainly consisting of non-speciﬁc but
frequently observed mixed symptoms from dimensional
aspects.17 Because the DMX-12 is a self-rating screening
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tool managed by patients themselves, it is possible to perform
DMX screening easily, without inconveniencing clinicians.
The DMX-12 (Table 1) almost comprehensively covers core
components from the “dip” symptoms (distractibility, irrit-
ability, restlessness, and inner tension) together with other
prevalent mixed symptoms such as racing/crowded thought,
mood lability, overreactivity, impulsivity, aggression, and
risk-taking behavior, which have been previously
reported.7,19
It should be noted that DMX symptoms were more pro-
minent in younger depressed subjects in the present study,
suggesting younger age at onset as a risk factor for mixed
psychopathology (Table 3). This is consistent with previous
studies, demonstrating a younger age with temperamental
mood lability26 and an earlier age at onset of the illness27,28
in DMX patients. These may at least partly support an
association between age and DMX in the context of tempera-
mental vulnerability and potential bipolarity.
Previous reports have also suggested a direct rela-
tionship between bipolarity and DMX.8,12,27,28 In fact,
bipolarity had positive effects on the total DMX-12 and
disruptive emotion/behavior subscale scores in the pre-
sent study. These results suggest the necessity to recog-
nize potential bipolarity in depressed individuals
manifested by disruptive emotion/behavior symptoms,
ie, dysphoria, irritability, aggression, and risk-taking
behavior, even though they do not apparently fulﬁll
criteria for hypomanic psychopathology. Thus, the pre-
sence of the disruptive emotion/behavior subscale symp-
toms during an MDE may be indicative of the future
need for bipolar treatments.
Meanwhile, it is obvious that the severity of DMX is
strongly dependent on that of core depressive symptoms
(Table 3). This may imply that the presence of clinically
signiﬁcant DMX is regarded as an expression of severe
depression, which may need more intensive treatment
intervention than non-mixed depression. Considering the
fact that the intrusion of mixed components into depres-
sion not only increases the severity of depression but also
requires more potent medication, ie, a shift from antide-
pressants to mood-stabilizing agents including atypical
antipsychotics,29 the biological basis of DMX in the con-
text of severity of depression needs to be clariﬁed in the
future.
In the present study, exploratory factor analysis
revealed a three-factor model for the symptomatological
structure of the DMX-12, consisting of the spontaneous
instability, vulnerable responsiveness, and disruptive
emotion/behavior subscales (Table 2). Patterns of distribu-
tions were apparently different among the scores on these
three subscales in the overall patients with MDEs, ie,
spontaneous instability was normally distributed, vulner-
able responsiveness was negatively skewed, and disruptive
emotion/behavior was positively skewed (Figure 2), which
may indirectly support the three-factor model as indepen-
dent components.
A considerable number of patients with MDEs have
various degrees of spontaneous instability symptoms
according to the normal distribution (Figures 1 and 2).
The spontaneous instability subscale contains instability
in thought process (racing/crowded thought and distract-
ibility), mood state (inner tension, restlessness, and mood
lability), and behavioral tendency (impulsivity). It is
assumed that these spontaneous instability symptoms
impair patients’ capability to maintain positive attention,
good concentration, rational decision-making, and
thoughtful behavior, thereby leading to a readiness for
careless, inconsistent, and impulsive responses to reality
during depressive mixed episodes.
The vulnerable responsiveness symptoms, such as
hypersensitivity and overreactivity, are common in most
patients with MDEs (Figures 1 and 2). Despite frequently
observed vulnerable responsiveness symptoms, such inter-
nalized features are not verbally expressed by patients with
MDEs and are unlikely to be focused on or intensively
interviewed as an extended depressive psychopathology by
clinicians. However, it is possible that hypersensitivity and
overreactivity to stimuli from surrounding others and
situations, together with lowered tolerance to inner frus-
tration and anxiety, may easily provoke loss of cognitive
control and mood dysregulation in patients with DMX
during MDEs. Therefore, an assessment of the vulnerable
responsiveness component appears to be important for
clinicians to plan a more deliberate strategy for cognitive
behavioral therapy to enhance patients’ self-awareness and
self-control, and to avoid self-induced deterioration in
mood symptoms.
The disruptive emotion/behavior symptoms, featuring
dysphoria, irritability, aggression, and risk-taking behavior,
are much less frequently observed during MDEs than any
other DMX-12 subscales (Figures 1 and 2), but are possibly
helpful in distinguishing patients with DMX from those
without DMX, by both Benazzi’s deﬁnition12,14,15 and
DMX-56 criteria (Table 4). These symptoms have also been
regarded as promoting factors for suicidal behavior,7,30,31 to
which clinicians should pay the greatest attention in
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assessing and managing the suicidal risks of patients with
DMX. Presumably, the disruptive emotion/behavior symp-
toms may be essential and core characteristics of DMX even
when different categorical criteria are applied.7,8,16
Furthermore, a report suggesting aggressiveness in depres-
sion as a feature of DMX13 may also support the ﬁndings on
disruptive behavior in the present study. The disruptive emo-
tion/behavior symptoms are relatively apparent to surround-
ing others and are sometimes externalized as interpersonal
friction and dangerous acting out. Accordingly, clinicians
should carefully conﬁrm whether such symptoms have
intruded only during mood episodes, and may need to con-
duct differential diagnosis of DMX during MDEs from bor-
derline personality disorder or disruptive, impulse control,
and conduct disorders, which rather constantly involve inter-
personal or behavioral problems irrespective of episodic
mood alterations.
As for the total score on the DMX-12, the median
score was 18 (36 as the full mark) in the overall patients
(Figure 2). This indicates that DMX ranging from mild to
severe degree during MDEs seems to be a commonly
observed phenomenon in a real-world clinical setting.
Before starting our study, it was hypothesized that patients
with DMX would show more severe disturbance in their
daily and social life than those without DMX. Contrary to
our clinical impression, the overall severity of mixed
symptoms assessed by total DMX-12 score was not
directly associated with patients’ GAF (Table 3). Despite
this negative result, clinicians should be warned that DMX
symptoms often provoke risky behavior, including suicide
attempts.7,30,31
This is a preliminary study and has several limita-
tions. First, the results were obtained from a relatively
small number of Japanese subjects. Second, since the
DMX-12 included many non-speciﬁc symptoms, its spe-
ciﬁcity for the diagnosis of DMX was not sufﬁciently
established. Third, assessment using frequency rather
than severity of DMX was conducted on the basis of
self-report scales by the DMX-12. Fourth, the reliability
and validity of the English version of the DMX-12 have
not yet been justiﬁed in other ethnic groups. Therefore,
the factor model of the DMX-12 should be re-examined
in larger number of subjects with various ethnicity and
languages. The speciﬁcity of the DMX-12 for DMX may
also be conﬁrmed not only in depressed patients but also
in non-depressed subjects, eg, those with anxiety disor-
ders and neurodevelopmental disorders. Conﬁrmatory
analyses may be required in the future, using new valid
methods such as clinimetric approaches, as suggested by
Carrozzino et al.32
Nevertheless, the quantiﬁcation of DMX using the
DMX-12 may open the door not only to routine screening
for DMX with considerable severity but also to assess-
ments of treatment response to probe drugs for DMX
through visible intra-individual changes in mixed
psychopathology.
Conclusions
The DMX-12 seems to be easy to use and helpful in
screening for DMX, in good agreement with conventional
categorical diagnoses. The DMX-12 has revealed that
various degrees of DMX during MDEs are commonly
observed in a real-world clinical setting. Clinicians should
be more sensitive to DMX, especially in severely
depressed younger individuals with potential bipolarity.
The disruptive emotion/behavior subscale of the DMX-
12 may be the most helpful in distinguishing patients
with DMX from those without mixed psychopathology.
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